Kodiak Sciences Shares Surge After Positive Phase 3 Trial Results for Wet AMD Treatments
Kodiak Sciences (NASDAQ: KOD) saw its stock rise by approximately 145% in early Monday trading following the announcement that two of its experimental therapies, Zenkuda and tabirafusp alfa tedromer, met key endpoints in a phase 3 trial for wet age-related macular degeneration. The DAYBREAK study evaluated these treatments as potential alternatives to current anti-VEGF injections used for managing this condition. The results suggest that the company's novel approach could offer improved efficacy or convenience compared to existing therapies, potentially disrupting an estimated multi-billion-dollar market in ophthalmology. Investors are reacting strongly due to the high unmet medical need and competitive landscape of wet AMD treatments.
Tickers: $KOD
Topics: biotech drug_development ophthalmology